Indivior PLC (INDV) Receives GBX 395.50 Consensus Target Price from Analysts
Indivior PLC (LON:INDV) has been assigned an average recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is GBX 395.50 ($5.32).
Several research firms have issued reports on INDV. Numis Securities Ltd reiterated a “buy” rating and issued a GBX 470 ($6.32) price objective on shares of Indivior PLC in a research report on Friday, September 15th. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 400 ($5.38) price objective on shares of Indivior PLC in a research note on Friday, September 15th. Jefferies Group LLC decreased their price objective on Indivior PLC from GBX 540 ($7.26) to GBX 358 ($4.81) and set a “buy” rating on the stock in a research note on Friday, September 8th. Citigroup Inc. reaffirmed a “neutral” rating and set a GBX 280 ($3.77) price objective on shares of Indivior PLC in a research note on Tuesday, September 5th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a GBX 470 ($6.32) target price on shares of Indivior PLC in a research report on Thursday, August 3rd.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Stock Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related stocks with our FREE daily email newsletter.